Patents by Inventor Jeremy Lee BARYZA
Jeremy Lee BARYZA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11066667Abstract: The present disclosure relates to compositions and methods for treating APOC3-related diseases such as: hypertriglyceridemia (e.g., Type V Hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including Type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a RNAi agent to APOC3.Type: GrantFiled: February 6, 2019Date of Patent: July 20, 2021Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Jan Weiler, William Chutkow, Jeremy Lee Baryza, Andrew Krueger, Junping Zhao
-
Patent number: 11008570Abstract: The disclosure relates to novel compounds and compositions comprising a RNAi agent comprising a novel compound as a 3? end cap. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference.Type: GrantFiled: January 16, 2019Date of Patent: May 18, 2021Assignee: Novartis AGInventors: Jeremy Lee Baryza, Marcel Blommers, Cesar Fernandez, Erin Geno, Alvar Gossert, Paulette Greenidge, Dieter Huesken, Juerg Hunziker, Francois Jean-Charles Natt, Anup Patnaik, Andrew Patterson, Jean-Michel Rene Rondeau, Jan Weiler, Meicheng Zhu
-
Patent number: 10792361Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.Type: GrantFiled: August 29, 2018Date of Patent: October 6, 2020Assignee: NOVARTIS AGInventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-Munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura West, Thomas Zabawa, Junping Zhao
-
Patent number: 10729775Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.Type: GrantFiled: June 28, 2018Date of Patent: August 4, 2020Assignee: NOVARTIS AGInventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura Ellen West, Thomas Zabawa, Junping Zhao
-
Patent number: 10519446Abstract: The disclosure relates to compositions comprising a HBV RNAi agent. In some embodiments, the HBV RNAi agent comprises a sense and an anti-sense strand, each strand being an 18-mer and the strands together forming a blunt-ended duplex, wherein the 3? end of at least one strand terminates in a phosphate or modified internucleoside linker and further comprises, in 5? to 3? order: a spacer; a second phosphate or modified internucleoside linker; and a 3? end cap. In some embodiments, the 3? end of both the sense and anti-sense strand further comprise, in 5? to 3? order: a spacer; a second phosphate or modified internucleoside linker; and a 3? end cap. The two strands can have the same or different spacers, phosphates or modified internucleoside linkers, and/or 3? end caps. The strands can be ribonucleotides, or, optionally, one or more nucleotide can be modified or substituted. Optionally, at least one nucleotide comprises a modified internucleoside linker.Type: GrantFiled: September 30, 2014Date of Patent: December 31, 2019Assignee: NOVARTIS AGInventors: Jeremy Lee Baryza, Marcel Blommers, Cesar Fernandez, Erin Geno, Alvar Gossert, Paulette Greenidge, Dieter Huesken, Juerg Hunziker, Francois Jean-Charles Natt, Anup Patnaik, Andrew Patterson, Jean-Michel Rene Rondeau, Jan Weiler, Meicheng Zhu, Meghan Holdorf
-
Publication number: 20190390196Abstract: The disclosure relates to novel compounds and compositions comprising a RNAi agent comprising a novel compound as a 3? end cap. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference.Type: ApplicationFiled: January 16, 2019Publication date: December 26, 2019Applicant: Novartis AGInventors: Jeremy Lee Baryza, Marcel Blommers, Cesar Fernandez, Erin Geno, Alvar Gossert, Paulette Greenidge, Dieter Huesken, Juerg Hunziker, Francois Jean-Charles Natt, Anup Patnaik, Andrew Patterson, Jean-Michel Rene Rondeau, Jan Weiler, Meicheng Zhu
-
Publication number: 20190233817Abstract: The present disclosure relates to compositions and methods for treating APOC3-related diseases such as: hypertriglyceridemia (e.g., Type V Hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including Type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a RNAi agent to APOC3.Type: ApplicationFiled: February 6, 2019Publication date: August 1, 2019Inventors: Jan Weiler, William Chutkow, Jeremy Lee Baryza, Andrew Krueger, Junping Zhao
-
Patent number: 10240153Abstract: The present disclosure relates to compositions and methods for treating APOC3-related diseases such as: hypertriglyceridemia (e.g., Type V Hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including Type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a RNAi agent to APOC3.Type: GrantFiled: January 11, 2017Date of Patent: March 26, 2019Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Jan Weiler, William Chutkow, Jeremy Lee Baryza, Andrew Krueger, Junping Zhao
-
Patent number: 10227588Abstract: The disclosure relates to novel compounds and compositions comprising a RNAi agent comprising a novel compound as a 3? end cap. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference.Type: GrantFiled: October 1, 2014Date of Patent: March 12, 2019Assignee: NOVARTIS AGInventors: Jeremy Lee Baryza, Marcel Blommers, Cesar Fernandez, Erin Geno, Alvar Gossert, Paulette Greenidge, Dieter Huesken, Juerg Hunziker, Francois Jean-Charles Natt, Anup Patnaik, Andrew Patterson, Jean-Michel Rene Rondeau, Jan Weiler, Meicheng Zhu
-
Publication number: 20180369386Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.Type: ApplicationFiled: August 29, 2018Publication date: December 27, 2018Inventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-Munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura West, Thomas Zabawa, Junping Zhao
-
Patent number: 10124065Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.Type: GrantFiled: March 6, 2014Date of Patent: November 13, 2018Assignee: Novartis AGInventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-Munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura West, Thomas Zabawa, Junping Zhao
-
Publication number: 20180296677Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.Type: ApplicationFiled: June 28, 2018Publication date: October 18, 2018Inventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura Ellen West, Thomas Zabawa, Junping Zhao
-
Patent number: 9988627Abstract: The disclosure relates to compositions comprising a RNAi agent having a novel format including a spacer subunit. The disclosure relates to compositions comprising a RNAi agent having a novel format: an 18-mer format with at least one internal spacer. These RNAi agents comprise a first and a second 18-mer strand, wherein the first strand is 18 ribonucleotides or 18 total ribonucleotides and spacer subunit(s), and the second strand is 18 total ribonucleotides and spacer subunit(s), wherein: each spacer subunit consists of: (a) a phosphate or modified internucleoside linker and (b) a spacer; a spacer subunit can be at any position in the strand; the two strands form a duplex with at least one blunt end; and the 3 end of one or both strands terminates in a phosphate or modified internucleoside linker and further comprises, in 5 to 3 order: a second spacer; a second phosphate or modified internucleoside linker, and a 3 end cap.Type: GrantFiled: October 6, 2014Date of Patent: June 5, 2018Assignee: NOVARTIS AGInventors: Jeremy Lee Baryza, Marcel Blommers, William Chutkow, Cesar Fernandez, Erin Geno, Alvar Gossert, Paulette Greenidge, Dieter Huesken, Juerg Hunziker, Francois Jean-Charles Natt, Anup Patnaik, Andrew Patterson, Jean-Michel Rene Rondeau, Jan Weiler, Meicheng Zhu
-
Publication number: 20170196979Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.Type: ApplicationFiled: September 27, 2016Publication date: July 13, 2017Applicant: Novartis AGInventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura Ellen West, Thomas Zabawa, Junping Zhao
-
Publication number: 20170137814Abstract: The present disclosure relates to compositions and methods for treating APOC3-related diseases such as: hypertriglyceridemia (e.g., Type V Hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including Type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a RNAi agent to APOC3.Type: ApplicationFiled: January 11, 2017Publication date: May 18, 2017Inventors: Jan Weiler, William Chutkow, Jeremy Lee Baryza, Andrew Krueger, Junping Zhao
-
Patent number: 9504747Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.Type: GrantFiled: March 7, 2014Date of Patent: November 29, 2016Assignee: Novartis AGInventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura Ellen West, Thomas Zabawa, Junping Zhao
-
Publication number: 20160304863Abstract: The disclosure relates to novel compounds and compositions comprising a RNAi agent comprising a novel compound as a 3? end cap. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference.Type: ApplicationFiled: October 1, 2014Publication date: October 20, 2016Inventors: Jeremy Lee BARYZA, Marcel BLOMMERS, Cesar FERNANDEZ, Erin GENO, Alvar GOSSERT, Paulette GREENIDGE, Dieter HUESKEN, Juerg HUNZIKER, Francois Jean-Charles NATT, Anup PATNAIK, Andrew PATTERSON, Jean-Michel Rene RONDEAU, Jan WEILER, Meicheng ZHU
-
Publication number: 20160244756Abstract: The disclosure relates to compositions comprising a RNAi agent having a novel format including a spacer subunit. The disclosure relates to compositions comprising a RNAi agent having a novel format: an 18-mer format with at least one internal spacer. These RNAi agents comprise a first and a second 18-mer strand, wherein the first strand is 18 ribonucleotides or 18 total ribonucleotides and spacer subunit(s), and the second strand is 18 total ribonucleotides and spacer subunit(s), wherein: each spacer subunit consists of: (a) a phosphate or modified internucleoside linker and (b) a spacer; a spacer subunit can be at any position in the strand; the two strands form a duplex with at least one blunt end; and the 3 end of one or both strands terminates in a phosphate or modified internucleoside linker and further comprises, in 5 to 3 order: a second spacer; a second phosphate or modified internucleoside linker, and a 3 end cap.Type: ApplicationFiled: October 6, 2014Publication date: August 25, 2016Inventors: Jeremy Lee BARYZA, Marcel BLOMMERS, William CHUTKOW, Cesar FERNANDEZ, Erin GENO, Alvar GOSSERT, Paulette GREENIDGE, Dieter HUESKEN, Juerg HUNZIKER, Francois Jean-Charles NATT, Anup PATNAIK, Andrew PATTERSON, Jean-Michel Rene RONDEAU, Jan WEILER, Meicheng ZHU
-
Publication number: 20160215288Abstract: The disclosure relates to compositions comprising a HBV RNAi agent. In some embodiments, the HBV RNAi agent comprises a sense and an anti-sense strand, each strand being an 18-mer and the strands together forming a blunt-ended duplex, wherein the 3? end of at least one strand terminates in a phosphate or modified internucleoside linker and further comprises, in 5? to 3? order: a spacer; a second phosphate or modified internucleoside linker; and a 3? end cap. In some embodiments, the 3? end of both the sense and anti-sense strand further comprise, in 5? to 3? order: a spacer; a second phosphate or modified internucleoside linker; and a 3? end cap. The two strands can have the same or different spacers, phosphates or modified internucleoside linkers, and/or 3? end caps. The strands can be ribonucleotides, or, optionally, one or more nucleotide can be modified or substituted. Optionally, at least one nucleotide comprises a modified internucleoside linker.Type: ApplicationFiled: September 30, 2014Publication date: July 28, 2016Inventors: Jeremy Lee Baryza, Marcel Blommers, Cesar Femandez, Erin Geno, Alvar Gossert, Paulette Greenidge, Dieter Huesken, Juerg Hunziker, Francois Jean-Charles Natt, Anup Patnaik, Andrew Patterson, Jean-Michel Rene Rondeau, Jan Weiler, Meicheng zhu, Meghan Holdorf
-
Publication number: 20160106842Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.Type: ApplicationFiled: March 6, 2014Publication date: April 21, 2016Inventors: Jeremy Lee BARYZA, Rohan Eric John BECKWITH, Keith BOWMAN, Crystal BYERS, Tanzina FAZAL, Gabriel Grant GAMBER, Cameron Chuck-Munn LEE, Ritesh Bhanudasji TICHKULE, Chandra VARGEESE, Shuangxi WANG, Laura WEST, Thomas ZABAWA, Junping ZHAO